NCT02835235View on ClinicalTrials.gov

A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 26, 2016

Primary Completion Date

July 7, 2017

Study Completion Date

July 7, 2017

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC9204-0530

Administered daily subcutaneously (s.c., under the skin)

DRUG

placebo

Administered daily subcutaneously (s.c., under the skin)

Trial Locations (2)

68502

Novo Nordisk Investigational Site, Lincoln

85283

Novo Nordisk Investigational Site, Tempe

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT02835235 - A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity | Biotech Hunter | Biotech Hunter